Merck & Co.
MRK
$124.03
+0.40%
Merck & Co., Inc. is a global pharmaceutical leader that develops and commercializes prescription medicines, vaccines, and animal health products across therapeutic areas including oncology, cardiometabolic disease, and infectious diseases. Its competitive identity is anchored by the blockbuster immuno-oncology drug Keytruda, which drives a substantial portion of revenue, and a robust vaccine portfolio featuring Gardasil and the recently expanded Capvaxive pneumococcal shot. The current investor narrative centers on Merck's ability to navigate the looming patent cliff for Keytruda, with recent news highlighting FDA label expansions for its vaccine business and ongoing pipeline developments, while merger mania in big pharma underscores the urgency to replenish growth drivers.…
MRK
Merck & Co.
$124.03
Related headlines
Investment Opinion: Should I buy MRK Today?
Rating: Hold. Merck is a defensive value play with strong current fundamentals, but the Keytruda patent cliff limits upside. The analyst consensus leans bullish with a mix of Buy and Hold ratings, and the average EPS estimate of $9.83 implies a forward P/E of 12.6x, which is reasonable.
Supporting Evidence: The trailing P/E of 14.4x is below the industry average of 18-20x, suggesting undervaluation. Revenue growth of 4.97% YoY is modest but stable, and the gross margin of 92.7% is industry-leading. Free cash flow of $12.36 billion supports a dividend yield of 3.1%, and the ROE of 34.7% indicates efficient capital use. The implied upside to the average analyst target is not calculable due to limited data, but the forward P/E suggests fair value.
Risks & Conditions: The biggest risks are Keytruda patent expiration and pipeline execution. This Hold would upgrade to Buy if the company announces a transformative acquisition or if pipeline data shows blockbuster potential, or if the P/E compresses below 12x. It would downgrade to Sell if revenue growth turns negative or if Keytruda faces a competitive setback. Overall, Merck appears fairly valued relative to its history and peers, trading at a discount that reflects its growth challenges.
Sign up to view all
MRK 12-Month Price Forecast
Merck is a defensive stock with solid current fundamentals but limited growth prospects. The valuation is attractive relative to peers, but the Keytruda patent cliff is a significant overhang. The base case of steady performance is most likely, with the stock trading in a range. An upgrade to bullish would require a clear pipeline catalyst, while a downgrade to bearish would follow a Keytruda-related setback. The neutral stance reflects the balanced risk/reward.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Merck & Co.'s 12-month outlook, with a consensus price target around $161.24 and implied upside of +30.0% versus the current price.
Average Target
$161.24
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$99 - $161
Analyst target range
Only 2 analysts cover Merck, which is unusually low for a large-cap stock, likely due to data limitations. The consensus recommendation is not explicitly provided, but based on the institutional ratings data (RBC Capital: Outperform, Citigroup: Neutral, Wells Fargo: Overweight, etc.), the sentiment leans bullish with a mix of Buy and Hold ratings. The average estimated EPS is $9.83, and the average revenue estimate is $74.04 billion, implying a forward P/E of ~12.6x based on the current price. The implied upside/downside cannot be calculated without target prices, but the forward P/E suggests modest expectations. The limited analyst coverage means less efficient price discovery and potentially higher volatility, as institutional interest may be lower than for peers. Investors should supplement with broader sell-side research and monitor for any coverage initiations or changes in ratings, which could act as catalysts.
Bulls vs Bears: MRK Investment Factors
Merck presents a mixed picture: strong current profitability and a low beta make it a defensive value play, but the looming Keytruda patent cliff and decelerating revenue growth are significant concerns. The bull case rests on the stock's attractive valuation (P/E 14.4x vs. industry 18-20x) and robust cash flow, while the bear case centers on the lack of a clear growth driver post-Keytruda. The single most important tension is whether Merck's pipeline and vaccine expansion can offset the revenue decline from Keytruda's patent loss. Currently, the evidence slightly favors the bull case given the valuation discount and defensive qualities, but the risk is real.
Bullish
- Strong Profitability and Cash Flow: Merck's Q4 2025 gross margin expanded to 92.7% from 75.5% a year ago, reflecting a favorable product mix. Free cash flow over the trailing twelve months is $12.36 billion, providing ample liquidity for dividends and strategic acquisitions.
- Attractive Valuation vs. Peers: The trailing P/E of 14.4x is below the industry median of 18-20x, suggesting the stock is undervalued relative to its peer group. The forward P/E of 12.8x implies modest earnings growth is already priced in.
- Defensive Characteristics with Low Beta: With a beta of 0.20, Merck is significantly less volatile than the market, making it a defensive holding. The stock has outperformed the S&P 500 over the past year (+47.0% vs. +20.6%), demonstrating resilience.
- Vaccine Portfolio Expansion: The recent FDA label expansion for Capvaxive to include at-risk children and teens strengthens Merck's vaccine franchise. This could offset some revenue pressure from Keytruda's eventual patent loss.
Bearish
- Keytruda Patent Cliff Looms: Keytruda drives a substantial portion of revenue, and its patent expiration is a major overhang. The PEG ratio of 1.81x indicates the stock is not cheap on a growth-adjusted basis, reflecting market skepticism about future growth.
- Modest Revenue Growth Decelerating: Q4 2025 revenue grew only 4.97% year-over-year, down from double-digit growth in prior years. This deceleration highlights the need for new catalysts to sustain momentum.
- Limited Analyst Coverage: Only 2 analysts cover Merck, which is unusually low for a large-cap stock. This can lead to less efficient price discovery and potentially higher volatility on news.
- High R&D Spending Pressure: R&D expenses were $3.692 billion in Q4 2025, representing 22.5% of revenue. The need to invest heavily in pipeline development to replace Keytruda revenue pressures margins.
MRK Technical Analysis
Merck is in a sustained uptrend, with the stock up 47.0% over the past year, significantly outperforming the S&P 500's 20.6% gain. The current price of $123.54 sits at 94.8% of its 52-week range ($76.66–$130.29), indicating the stock is near the top of its range and reflecting strong bullish momentum. This positioning near highs suggests continued investor confidence but also raises the risk of overextension, as the stock has rallied sharply from its 52-week low. Short-term momentum is mixed: the 1-month change of +3.7% shows recent acceleration, while the 3-month change of +1.7% is more subdued, diverging from the powerful 1-year trend. This divergence could signal a temporary consolidation phase after a strong run, rather than a trend reversal, as the stock has pulled back from its June 2026 highs near $130. The beta of 0.20 indicates Merck is significantly less volatile than the market, making it a defensive holding. Key support lies at the 52-week low of $76.66, while resistance is at the 52-week high of $130.29. A breakout above $130.29 would signal renewed upside momentum, while a breakdown below recent support near $115 (the May 2026 low) could indicate a deeper correction.
Beta
0.20
0.20x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$77-$130
Price range past year
Annual Return
+48.8%
Cumulative gain past year
| Period | MRK Return | S&P 500 |
|---|---|---|
| 1m | +4.2% | +1.0% |
| 3m | +3.4% | +7.9% |
| 6m | +11.7% | +8.5% |
| 1y | +48.8% | +20.1% |
| ytd | +16.5% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRK Fundamental Analysis
Merck's revenue trajectory is stable with modest growth; the most recent quarter (Q4 2025) reported revenue of $16.4 billion, up 4.97% year-over-year from $15.624 billion in Q4 2024. Over the trailing four quarters, revenue has ranged from $15.5B to $17.3B, with the Pharmaceutical segment contributing $14.84B (90.5% of total) in the latest quarter, while Animal Health added $1.505B. Growth is driven by Keytruda and vaccine sales, though the pace is decelerating from the double-digit growth seen in prior years, highlighting the need for new catalysts. Profitability is robust: net income for Q4 2025 was $2.963 billion, with a net margin of 18.1%, while gross margin expanded to an impressive 92.7% (up from 75.5% in Q4 2024), reflecting a favorable product mix and cost controls. Operating margin of 53.3% is strong, though net income was impacted by a $5.316 billion other expense line. The balance sheet is healthy: debt-to-equity is 0.96, and free cash flow (TTM) stands at $12.36 billion, providing ample liquidity for dividends and strategic acquisitions. Return on equity (ROE) is 34.7%, indicating efficient capital use, while the current ratio of 1.54 suggests adequate short-term liquidity.
Quarterly Revenue
$16.4B
2025-12
Revenue YoY Growth
+5.0%
YoY Comparison
Gross Margin
92.7%
Latest Quarter
Free Cash Flow
$12.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRK Overvalued?
Since net income is positive ($2.963B in Q4 2025), the primary valuation metric is the P/E ratio. The trailing P/E is 14.4x, while the forward P/E is 12.8x, implying the market expects earnings growth over the next year. The gap between trailing and forward P/E suggests modest earnings expansion is priced in. Compared to the industry average (Drug Manufacturers - General), Merck's trailing P/E of 14.4x is at a discount to the sector median of roughly 18-20x, reflecting its mature growth profile and patent cliff risks. However, its PEG ratio of 1.81x indicates the stock is not cheap on a growth-adjusted basis, as earnings growth is expected to be moderate. Historically, Merck's P/E has ranged from 9x to 23x over the past five years; the current 14.4x is near the lower end of that range, suggesting the stock is not overvalued relative to its own history. This could imply a value opportunity if the company successfully navigates patent expirations, but also reflects market skepticism about future growth.
PE
14.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -57x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Merck's financial health is solid, but the heavy reliance on Keytruda (a significant portion of pharmaceutical revenue) creates concentration risk. The debt-to-equity ratio of 0.96 is manageable, but net income in Q4 2025 was impacted by a $5.316 billion other expense line, highlighting earnings volatility. Free cash flow of $12.36 billion provides a cushion, but any disruption to Keytruda sales could severely impact cash generation. The gross margin expansion to 92.7% is impressive but may not be sustainable if product mix shifts.
Market & Competitive Risks: The stock's low beta of 0.20 makes it defensive, but it also means limited upside in a strong bull market. Valuation compression is a risk if the market re-rates the stock lower due to growth concerns; the current P/E of 14.4x is near the low end of its 5-year range (9x-23x), suggesting limited downside from multiple contraction. Competitive threats include Pfizer's pneumococcal vaccine and other immuno-oncology drugs challenging Keytruda. Recent news highlights merger mania in big pharma, which could leave Merck at a disadvantage if it fails to make accretive acquisitions.
Worst-Case Scenario: If Keytruda faces an earlier-than-expected patent loss or a competitive setback, and pipeline drugs fail to materialize, the stock could re-rate to its 52-week low of $76.66. From the current price of $123.54, this represents a potential loss of -38%. This scenario would likely be triggered by a major clinical trial failure or regulatory setback for a key pipeline asset, combined with a broader market downturn.
FAQ
The primary risk is the Keytruda patent cliff, as the drug drives a substantial portion of revenue. A second risk is pipeline execution: if new drugs fail to replace Keytruda, growth could stall. Third, the low beta of 0.20 means the stock may underperform in a strong bull market. Fourth, limited analyst coverage (only 2 analysts) can lead to less efficient price discovery. The most severe risk is a -38% decline to the 52-week low of $76.66 if Keytruda faces an early patent loss.
The base case scenario (55% probability) sees the stock trading between $115 and $130 over the next 12 months, driven by steady but unspectacular results. The bull case (25% probability) targets $130-$145, fueled by pipeline successes or a transformative acquisition. The bear case (20% probability) sees the stock falling to $90-$105 if Keytruda faces a setback. The most likely outcome is the base case, with the stock remaining range-bound as the market awaits clarity on the post-Keytruda growth story.
Merck appears undervalued relative to its industry, with a trailing P/E of 14.4x versus the sector median of 18-20x. However, the PEG ratio of 1.81x indicates that the stock is not cheap on a growth-adjusted basis, as earnings growth is expected to be modest. Historically, the stock has traded between 9x and 23x P/E over the past five years, so the current level is near the lower end, suggesting it is not overvalued. The market is pricing in the risk of Keytruda's patent loss, which explains the discount. Overall, the stock is fairly valued given its growth challenges.
Merck is a good buy for investors seeking a defensive, income-generating stock with a low beta of 0.20 and a dividend yield of 3.1%. The trailing P/E of 14.4x is below the industry average, suggesting value. However, the stock faces a significant risk from the Keytruda patent cliff, which could pressure future growth. For long-term investors with a moderate risk tolerance, it is a reasonable hold, but growth-oriented investors may find better opportunities elsewhere. The risk/reward is balanced, with limited upside but also limited downside given the defensive nature.
Merck is more suitable for long-term investment due to its defensive nature, low beta of 0.20, and stable dividend yield of 3.1%. Short-term traders may find limited volatility, as the stock's beta is low and price movements are modest. The stock is best held for at least 3-5 years to ride out the Keytruda patent transition and benefit from pipeline developments. For income-focused investors, it can be a core holding. Growth investors should look elsewhere for higher upside.